August 26, 2020
Dermavant Reports Positive Phase 3 Results for Tap ...
Read More
June 16, 2020
Dermavant Announces Publication in JAAD of Seconda ...
Read More
June 9, 2020
Dermavant Completes Patient Enrollment for Long-Te ...
Read More
May 26, 2020
Dermavant Announces Publication in JAAD of Seconda ...
Read More
April 2, 2020
Dermavant Completes Patient Enrollment for Two Pha ...
Read More
January 15, 2020
Dermavant Enters into Exclusive License Agreement ...
Read More
December 3, 2019
Dermavant Announces First Patient Dosed in Phase 2 ...
Read More
June 5, 2019
Dermavant Sciences Announces First Patient Dosed i ...
Read More
May 15, 2019
Dermavant Sciences Appoints Timothy S. Nelson and ...
Read More
March 27, 2019
Dermavant Sciences Announces Appointment of Cyril ...
Read More
February 21, 2019
Dermavant Sciences to Present Data on Tapinarof fo ...
Read More
January 2, 2019
Dermavant Sciences Announces Appointment of Dr. Ph ...
Read More
December 6, 2018
Dermavant Sciences to Present New Data on Cerdulat ...
Read More
November 15, 2018
Dermavant Appoints Todd Zavodnick as Chief Executi ...
Read More
October 11, 2018
Dermavant Sciences to Present Tapinarof Phase 2B D ...
Read More
September 4, 2018
Dermavant Announces Changes to Leadership and Boar ...
Read More
August 21, 2018
Dermavant Sciences Announces Closing of Transactio ...
Read More
July 12, 2018
Roivant subsidiary Dermavant Sciences signs agreem ...
Read More
June 19, 2018
Dermavant to Present at JMP Securities Life Scienc ...
Read More
April 3, 2018
Dermavant Expands Pipeline and Strengthens Executi ...
Read More
